Navigation Links
Quantum Materials Corp and Nanoaxis Announce Technology Alliance
Date:9/20/2011

Quantum Material Corporation and its subsidiary Solterra Renewable Resources, added, "This alliance will foster a breakthrough in theranostic science as it enables mass production of Nanoaxis nanomedicine product pipeline.  The goal is to make these biologically adapted quantum dots the ideal choice for in vitro and in vivo applications for high throughput, efficient and cost effective applications in the biological and medical market spaces. Quantum Materials' ability to create tetrapod quantum dots of various materials, shapes, sizes and characteristics that can serve as delivery platforms for Nanoaxis products will allow for rapid commercial development."

"This is an exciting moment for our industry. We see this Technology Alliance between Nanoaxis and Quantum Materials Corp as bringing industrial scale production to the cutting edge of nanomedicine research.  The synergy of the combined technologies is enhanced by the cooperation of our two companies' seasoned management and research teams and we believe this partnership will be the catalyst of many biomedicine advances," said Dr. Krishnan Chakravarthy, Nanoaxis, LLC President and CEO.

Siddhartha Kamisetti, Director of Global Strategy at Nanoaxis, commented, "This alliance opens the door for pioneering developments in the biomedical space and presents a significant opportunity to assist people suffering from a host of diseases and ailments throughout the world."

About Quantum Materials Corporation, Inc. & Nanoaxis, LLC

QUANTUM MATERIALS CORPORATION has a steadfast vision that advanced technology is the solution to the most challenging of global issues. Quantum Materials Corporation is devoted to the deployment of technologies to invigorate the development of disruptive solutions through cost reduction and moving laboratory discovery to commercialization with volume manufacturing methods to establish a growing line of innovative high performance products.
'/>"/>

SOURCE Quantum Materials Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Quantum Immunologics, Inc. and the South Alabama Medical Science Foundation Announce an Early Clinical Evaluation of a Novel Immuno-therapeutic Vaccine for Treating Advanced Human Breast Carcinomas
2. Binder Biomedical, Inc. Announces the Release of the X-GRAFT(TM) Interspinous Device, as Part of Their QUANTUM(TM) Line of Spinal Allograft Devices, Manufactured at the University of Miami Tissue Bank
3. Quantum Signal and Delphinus Medical Technologies Awarded MEGA Funding to Expand in Ann Arbor Area
4. Block Engineering Introduces Family of Quantum Cascade Laser Mid-IR Spectrometers
5. Pharmasset Initiates QUANTUM, a Phase 2b Interferon-Free Trial of PSI-7977 and PSI-938 for All HCV Genotypes
6. National Stem Cell Holding, Inc. Discovers Non-Embryonic Biomaterials that Promote Tissue Repair
7. Demand for Spanish-Language Cancer Web Materials Quadruples; Internet Resources and Access Remain Scarce
8. In Blood Vessel Stents, Innovative Materials Allow Better Control, Delivery of Gene Therapy
9. Leading Healthcare System Decreases MRSA Infection Rate by 53 Percent - Offers Protocol & Educational Materials Free of Charge to Other Organizations
10. New Technology Reduces Risk of IVF Laboratory Mistakes by Electronically Identifying Sperm, Eggs and Other Materials for Each Patient
11. Reportlinker Adds European Markets for Orthopedic Biomaterials 2009 (15 Countries)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... LOUISVILLE, Ky. , Jan. 15, 2014  Manufacturers, ... technologies must be able to protect their most ... (Logo: http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because ... Industry, it steadfastly remains one of the most ...
(Date:1/15/2014)... Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... Symphony® CGM System as a non-invasive, wireless continuous glucose ... , Executive Chairman and Interim CEO of Echo Therapeutics, ... Annual Equity Conference. Mr. Doman will ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... India Drug Forecast and Market Analysis to ... PharmaPoint: Atopic Dermatitis - India Drug ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
...  Swedish Covenant Hospital today announced the success of its ... Guided Surgery by Brainlab, the ultimate command and control ... option to use image guidance for a prone, occipital ... visualization in these types of procedures, and makes me ...
... a leading Contract Research Organization (CRO) and services provider for ... has been appointed Chief Medical Officer. In this role, Dr. ... management related to genae,s research services. "I am ... will be of great benefit to the many aspects of ...
Cached Medicine Technology:Curve Image Guided Surgery Provides Swedish Covenant Hospital With a State-of-the-Art Command and Control Center for Information-Guided Surgery 2Curve Image Guided Surgery Provides Swedish Covenant Hospital With a State-of-the-Art Command and Control Center for Information-Guided Surgery 3genae Appoints Chief Medical Officer 2
(Date:4/18/2014)... The Gerontologist reports that among ... a decrease in anxiety about death and increases in ... lives. In particular, listening to gospel music is associated ... increase in sense of control. , These associations are ... individuals of both low- and high-socioeconomic status. , The ...
(Date:4/18/2014)... Medicine researchers have been awarded two-year grants for their ... this month. Of the 110 initial submissions to the ... Program, only four projects were funded, three of which ... Powell, M.D., Ph.D.; G. William Wong, Ph.D.; and Elias ... of oncology, will use his $500,000 proof of principle ...
(Date:4/18/2014)... 2014) Benaroya Research Institute at Virginia Mason (BRI) ... particular molecule in metastatic breast cancer reduces both the ... metastases. BRI scientists have found in models of the ... 60 - 80 percent and can keep the tumor ... million five-year grant comes from the National Cancer Institute ...
(Date:4/18/2014)... (April 18, 2014) ― A new study in the ... patterns in health-related Google searches reveals a recurring pattern ... , Investigators from San Diego State University, ... Monday Campaigns, analyzed "healthy" Google searches (searches that included ... diet") originating in the U.S. from 2005 to 2012. ...
(Date:4/18/2014)... could lead to potential new treatments for breaking the ... , Fibrosis, or scarring, is a hallmark of the ... can lead to serious organ damage and, in some ... centers on findings made by Swati Bhattacharyya, PhD, research ... a specific protein plays in promoting fibrosis. , ...
Breaking Medicine News(10 mins):Health News:Religious music brings benefit to seniors' mental health 2Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:New research shows people are thinking about their health early in the week 2Health News:New clues on tissue scarring in scleroderma 2
... probability of tumor response ... and accelerates drug development, SEATTLE, Oct. ... Systems Medicine, LLC (SM), a,wholly-owned subsidiary of CTI, today announced ... trial of brostallicin used in combination,with either bevacizumab or irinotecan, ...
... results include 19 percent sales growth and EPS of $.85, Q3 pro forma adjusted results ... ... EPS guidance updated to $3.50 - $3.55, or ... $2.76 - $2.81 reported, INDIANAPOLIS, Oct. 18 Eli Lilly and Company,(NYSE: LLY ) ...
... Consecutive Quarter, DEERFIELD, Ill., Oct. 18 Baxter ... results for the period,ended September 30, 2007 and raised ... quarter net income of $395 million increased 6 percent ... 2006. Net earnings per,diluted share of $0.61 increased 7 ...
... Blood Pressure Cuff and Weight Scale Added to Our ... Telemedicine Product ... Sheets: XMDC) announced the company has added two new,Bluetooth(R) enabled telemedicine ... care, hospitals, long term care,facilities, and physician groups. "The addition ...
... More than half of holiday shoppers (57,percent) plan ... good cause*. This,year, choose a gift that will brighten ... the seventh leading cause of death,in the United States. ... families struggling with,Alzheimer,s or support innovative research grants, which ...
... Inc. (NASDAQ:QLTI;,TSX:QLT) today reported that Novartis AG announced ... million for the quarter ended,September 30, 2007. This ... the,third quarter of 2006 and a 17.9% decline ... in the U.S. for the quarter were approximately ...
Cached Medicine News:Health News:U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors 2Health News:U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors 3Health News:U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors 4Health News:Lilly Delivers Strong Third-Quarter Results 2Health News:Lilly Delivers Strong Third-Quarter Results 3Health News:Lilly Delivers Strong Third-Quarter Results 4Health News:Lilly Delivers Strong Third-Quarter Results 5Health News:Lilly Delivers Strong Third-Quarter Results 6Health News:Lilly Delivers Strong Third-Quarter Results 7Health News:Lilly Delivers Strong Third-Quarter Results 8Health News:Lilly Delivers Strong Third-Quarter Results 9Health News:Lilly Delivers Strong Third-Quarter Results 10Health News:Lilly Delivers Strong Third-Quarter Results 11Health News:Lilly Delivers Strong Third-Quarter Results 12Health News:Lilly Delivers Strong Third-Quarter Results 13Health News:Lilly Delivers Strong Third-Quarter Results 14Health News:Lilly Delivers Strong Third-Quarter Results 15Health News:Lilly Delivers Strong Third-Quarter Results 16Health News:Lilly Delivers Strong Third-Quarter Results 17Health News:Lilly Delivers Strong Third-Quarter Results 18Health News:Lilly Delivers Strong Third-Quarter Results 19Health News:Baxter Reports Strong Third Quarter Sales and Earnings 2Health News:Baxter Reports Strong Third Quarter Sales and Earnings 3Health News:Baxter Reports Strong Third Quarter Sales and Earnings 4Health News:Baxter Reports Strong Third Quarter Sales and Earnings 5Health News:Baxter Reports Strong Third Quarter Sales and Earnings 6Health News:Baxter Reports Strong Third Quarter Sales and Earnings 7Health News:Baxter Reports Strong Third Quarter Sales and Earnings 8Health News:Baxter Reports Strong Third Quarter Sales and Earnings 9Health News:Baxter Reports Strong Third Quarter Sales and Earnings 10Health News:Baxter Reports Strong Third Quarter Sales and Earnings 11Health News:Baxter Reports Strong Third Quarter Sales and Earnings 12Health News:Baxter Reports Strong Third Quarter Sales and Earnings 13Health News:Baxter Reports Strong Third Quarter Sales and Earnings 14Health News:Baxter Reports Strong Third Quarter Sales and Earnings 15
Equinox is a truly unique approach to cosmetic enhancement contact lenses and is worn as a conventional wear lens....
... QuantiGene 2.0 is a reagent and ... expression knockdown. The high throughput plate based ... assay that provides a unique approach for ... reporter signal using branched DNA (bDNA) technology. ...
Xsera Rapid HIV-1/2 Antibody Controls are unassayed positive and negative quality control materials used for monitoring the performance of qualitative rapid HIV-1 and HIV-2 test kits....
...
Medicine Products: